NCT03554486View on ClinicalTrials.gov

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

March 30, 2019

Study Completion Date

March 30, 2019

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Fiasp

Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system

DRUG

Novolog

Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system

Trial Locations (2)

94304

Stanford University, Palo Alto

94305

Stanford, Palo Alto

Sponsors

Collaborators (1)

Medtronic
All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Stanford University

OTHER